@Raj143, We are in the exclusivity period but if an unsolicited bid from a third party comes along and Mayne accepts it, my reading is that there's no break fee.
Regarding what the report is going to be on Wednesday, let's wait and see, there's been a lot of chatter here about costs ballooning out but if that were the case, underlying EBITDA would not be in the $30-32M range (this figure includes direct and indirect costs). That's not to say that there's perhaps some big adjustment below the line that we are all unaware of. The so called increased in costs to drive growth referred by some posters here refers to the guidance for the second half not the first half. I maintain that EPS will be -$0.2 to -$0.4 a massive improvement on the -$0.8 reported in the equivalent period last year. I may be proven wrong but that is my analysis.
"Looking forward to 2H FY25, the Company expects to see continued growth, some seasonal costimpacts from patient payment programs as deductibles reset, and an increase in promotionalexpenses for Women’s Health products to drive additional growth."
MYX Price at posting:
$7.20 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)